Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Next Previous
Trial Profile

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Durvalumab (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ACTS 30

Most Recent Events

  • 06 Jun 2023 Results of phase 1b trial (n=30) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 31 Jan 2021 Planned number of patients changed from 39 to 30.
  • 31 Jan 2021 Interim Results (n=14; data cut off date: 25 Feb, 2020) of the safety and feasibility of the combination of neoadjuvant chemoradiotherapy with durvalumab (PD-L1 inhibitor) in potentially resectable stage III Non-small cell lung cancer, presented at the 2020 World Conference on Lung Cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top